This study investigates the effectiveness of neoadjuvant chemotherapy compared to adjuvant chemotherapy in advanced ovarian cancer patients, analyzing data from 574 cases treated in Lithuania between 1993 and 2000.
The findings reveal no significant differences in overall survival or progression-free survival rates between patients who received neoadjuvant chemotherapy and those who had adjuvant chemotherapy, regardless of their cancer stage.
The study concludes that neoadjuvant chemotherapy does not show a benefit over adjuvant chemotherapy concerning survival outcomes or the rates of successful cytoreductive surgery in advanced ovarian cancer patients.
Primary cytoreductive surgery remains the standard care in advanced ovarian cancer. Optimal cytoreductive surgery is defined as a residual tumor load less than 1 cm. after operation.